Navigation Links
China Biologic Products Announces Strong 2008 Results
Date:4/1/2009

Business Outlook

Commencing January of 2008, the SFDA implemented stricter pharmaceutical GMP inspection standards designed to intensify supervision of drug producers and ensure drug quality. The new inspection standards include 259 articles, up from 225 articles in the previous standards, covering areas such as the sourcing of raw materials, manufacturing processes, self-inspection processes at each stage of production and transportation. China Biologic's newly constructed facility with 700 tons of annual production capacity for plasma-based products was certified to be in compliance with the new standards. The renewed GMP Certification replaces the current GMP certification for the production facility, which was renewed in 2004. The GMP certification is valid for five years following the date of issuance.

The plasma-based industry has been immune from the impact of the ongoing global financial crisis as the demand for the products has out-paced supply. As a result, the Company's selling price, cost of revenue and operating expenses during 2008 were not impacted by the global financial turmoil.

Currently, China Biologic is the only approved manufacturer of plasma-based biopharmaceuticals in Shandong Province, which has a population of 93 million. China Biologic currently produces about 200 tons of plasma-based products per year and has 700 tons of annual production capacity. The Company is pursuing an aggressive acquisition strategy aimed at becoming the largest non-state-owned producer of plasma-based products in China.

On September 26, 2008, the Company agreed to acquire a 90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin"). Dalin owns 54% of the equity interest in Qianfeng Biological Products Co., Ltd. ("Qianfeng"), one of the largest plasma-based biopharmaceutical companies in China, located in Guiyang, Guizhou Province. The acquisition will
'/>"/>

SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... May 20, 2013 Researchers from the ... connection between lower back pain, and the acne causing P.acnes ... the system the bacteria seek out oxygen deprived location to ... the spinal column, P.acnes has the ability to live in ... Fernando Perez, a spokesman for “ The best acne treatment ...
(Date:5/20/2013)... May 20, 2013 In Early 2013, ... field of biotoxin related illnesses , announced his vision ... able to advance his protocol for treating Chronic Inflammatory ... the third physician to achieve certification in the Shoemaker ... able to practice the Shoemaker Protocol in other parts ...
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2
... Milestone triggers $10 million payment from Eli Lilly ... - BioMS Medical Corp. (TSX:,MS), a leading developer ... that the independent Drug Safety Monitoring Board (DSMB) ... analysis of efficacy,and safety and has recommended that ...
... Scotland, S.D. to start in Q4 ,08. , ... ... Coalition for Ethanol conference, http://www.poet.com [POET] announced that construction ... facility later this year. The pilot plant will be adjacent to ...
... ATSI ), manufacturer and marketer of state-of-the-art ... at the Fourth,Annual Noble Financial Equity Conference at ... Financial Officer of ATS Medical, will,present at 2:30 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), Attendance at ...
Cached Biology Technology:BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Testing people for heart disease might be just a ... created by a team of researchers from Harvard and Northeastern ... The FASEB Journal ( http://www.fasebj.org ), they describe ... cells needed to build vascular tissue, called endothelial progenitor cells, ...
... Boston, MA June 1, 2009 REGiMMUNE Corporation ... combination with a low-dose of Sirolimus, demonstrated enhanced efficacy ... and acute Graft-versus-Host disease (GvHD). This data is ... Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone ...
... years modeled how different species are likely to respond ... populations within a species and the interactions between species, ... June issue of BioScience , by Eric Post ... these limitations can be avoided. Their approach, which relies ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2